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Summary 
Evaluation of: Intramyocardial stem cell injection in patients with ischemic 
cardiomyopathy: functional recovery and reverse remodeling. 
Williams AR, Trachtenberg B, Velazquez DL, et al. Circ Res108, 792-6 (2011). 
Transcatheter, intramyocardial injections of bone marrow-derived cells produce 
reverse remodeling in large animal models of ischemic cardiomyopathy. A variety 
of adult stem and progenitor cells from different sources have already been 
examined for their potential to promote cardiac repair and regeneration after 
myocardial infarction.This article reviews a recent study by Williams and 
colleagues who test the hypothesisthat transcatheter, intramyocardial injections 
of autologous bone marrow progenitor cells(mononuclear or mesenchymal stem 
cells) in left ventricular scar and border zone improve regional contractility of a 
chronic myocardial scar, and these changes predict subsequent reverse 
remodeling.All patients tolerated the procedure with no serious adverse events. 
At 1 year cardiac MRI demonstrated a decrease in end diastolic volume, a trend 
toward decreased end systolic volume, decreased infarct size, and improved 
regional LV function. This evaluation focuses on the findings and limitations of 
the study and provides bases for future promising clinical trials. 
Keywords 
Heart failure, Ischemic cardiomyopathy, MRI, Cardiac cell therapy, Mesenchymal 
stem cells 
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This article reviews the recent paper by Williams et al.1 showing that 
transcatheter intramyocardial injections of autologous bone marrow progenitor 
cells may improve regional contractility of a chronic myocardial scar, and that 
these changes predicted subsequent reverse remodeling. Heart failure (HF) is a 
disease of increasing concern around the world. Fifty percent of all hospital 
admissions in patients over 65 years of age in the United States are for cardiac 
failure. It has a significant economic burden, and therapies today for these 
patients are limited. Stem cell therapy in this population has shown enormous 
promise to provide benefit to patients.A variety of adult stem and progenitor cells 
from different sources have already been examined for their potential to promote 
cardiac repair and regeneration after acute myocardial infarction (AMI). Although 
early, small-scale clinical studies underscored the potential effects of cell-based 
therapy largely by using bone marrow cells, subsequent randomized-controlled 
trials have revealed mixed results that might relate, at least in part, to differences 
in study design and techniques, e.g. differences in patient population, cell 
sources and preparation, and endpoint selection. Recent meta-analyses 2 have 
supported the notion that administration of bone marrow mononuclear cells 
(BMCs) may improve cardiac function on top of standard therapy after AMI and 
our group recently showed the effect of BMCs on myocardial viability 3. Among 
the next steps, patients with chronic ischemic HF are potential targets for cell 
therapy because of the limits of available treatments and a lack of emerging 
therapies. Cardiac cell-based therapy currently also lacks clinical comparison 
studies of cell types, a situation of increasing concern given the growing number 
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of cell types contemplated for therapy4. Focusing on these issues, Williams et 
al.1 initiated a program of cell therapy using two types of bone marrow-derived 
stem cells, in which the pilot study is presented here. 
 
Methods 
In the study, eight patients with ischemic cardiomyopathy (4 months to 11 years 
after an AMI) received transendocardial injections in left ventricular (LV) scar and 
border zone of autologous bone-marrow-derived cells that had been harvested 
from iliac crest. Four patients were treated with BMCs and four with cultured 
mesenchymal stem cells (MSCs). The investigators used magnetic resonance 
imaging (MRI) to evaluate cardiac structure and function at baseline and at three, 
six, and 12 months after cell therapy. Only 4 patients had longitudinal 
assessment of scar size because of the presence of implantable cardioverter 
defibrillators. Thus, this study does not have a placebo nor control comparison 
group and lacks the power to identify any superiority between MSCs or BMCs.  
 
Results 
The primary outcome of this phase 1 study was to assess the safety of 
transendocardial administration, and none of the patients experienced a serious 
adverse event. Secondary endpoint analyses performed with MRI in 4/8 patients 
showed at 1-year follow-up a decrease in end-diastolic volume (p=0.03) and a 
trend toward decreased in end-systolic volume (p=0.06) after cell administration 
compared to baseline. Authors stated a strong correlation between changes in 
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end-systolic volume and end-diastolic volume with a parallel decrease in 
chamber volume. However, ejection fraction and left ventricular mass did not 
significantly change, but there was a significant decrease in infarct size of 18.3% 
(p<0.05). The authors conclude that human autologous bone-marrow progenitor 
cells may increase regional contractility of injected myocardial scar tissue within 
three months of treatment, and these functional changes are associated with 
later reverse remodeling. Several limits are pointed out, including the small 
patient number and the lack of placebo or control group.    
 
Discussion 
In preclinical porcine studies, Hare’s group previously demonstrated that 
transcatheter, intramyocardial injection of bone marrow–derived progenitor cells 
to chronically scarred myocardium improves LV regional function, reduces scar 
size, and creates reverse remodeling 5. The translation of basic research 
described in this clinical trial occurs relatively early on in the evolution of this new 
field of research. What has been lost in translation is our understanding of the 
value of surrogate end points in cardiac cell therapy clinical trials 6. Surrogate 
end points are useful ways of looking for effects that may have clinical relevance. 
Cardiac MRI represents a promising modality for a tissue characterization of AMI, 
beyond traditional morpho-functional indexes. Moreover, cardiac MRI parameters 
may in the future be used with greater frequency as surrogate imaging end points 
of morbidity and mortality for testing novel therapeutic strategies as in the case of 
cellular-based therapies7, 8. However, electronic devices such as pacemakers, 
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defibrillators, infusion pumps, and others are still considered as contraindications 
in most of the patients, therefore preventing the use of MRI in patients at risk of 
having such devices, including patients with defibrillator because of low ejection 
fraction and HF (ESC guidelines 2010). Alternative methods for exploring 
myocardial viability also include nuclear imaging modalities9(SPECT and PET), 
and low-dose dobutamine stress echocardiography.  
The clinical relevance of small changes in surrogate measures with respect to 
their overall consequence is poorly understood. The literature is now full of 
similar small trials (Table 1) that were designed to test for safety but report 
effects despite a lack of statistical power. Although these trials demonstrated 
significant improvements in clinical outcome, they were associated with very 
small changes in cardiac function4, 10. MRI provides a unique opportunity to 
image the in vivo structural and functional changes after bone-marrow stem-cell 
therapy for the heart. Although, the infarction zone improvements were evident 
as early as 3 months and persisted out to 1 year and strongly correlated to the 
improvements in end-diastolic volume and end-systolic volume, the main limit of 
this study is the extrapolation of benefits with only 4 patients.  
 
Comparing cell type administration 
BMCs have already been administered in patients with ischemic cardiopathy 
11,12. Adult mesenchymal stem cells (MSCs) have shown promise for heart 
repair and have been explored for possible cardiac regeneration. The advantage 
of this cell population is the ease of acquisition and expansion in culture. 
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However, their use in cardiac repair, as compared to bone marrow mononuclear 
cells is still at early stage. To date only two clinical trials have assessed the 
therapeutic potential of autologous MSCs for AMI 13,14. In both studies, MSCs 
were selected by culture and have shown that intracoronary MSC administration 
is safe and feasible. So far, there is no available publication on intramyocardial 
administration of MSCs for chronic HF but only one study in the setting of 
refractory angina 15. 
 
Future Perspectives 
The study by Williams et al.1 is the pilot phase of the Transendocardial 
Autologous Cells in Ischemic Heart Failure (TAC-THF) study (NCT00768066), 
aimed at evaluating the safety of cells administered via the BioCardia Helical 
Infusion Catheter (BioCardia, San Carlos, CA). TAC-HFT study will be the first 
study to compare BMCs and MSCs in humans in a phase II, randomized, double-
blinded, placebo-controlled study. The end points will be hospitalization plus 
death as well as the MRI end points used in the pilot study. Development of new 
systems for cell therapy product administration is of high interest since the 
number of patients with ischemic HF is increasing. Most often used in clinical 
trials (as referred to previous publications and referenced ongoing trials in 
clinicaltrials.org website), the NOGA mapping system has already been 
evaluated in humans but suffered from a long time period data acquisition 
allowing the 3D reconstruction of the left ventricle. However, in conjunction with 
the new NOGA® XP mapping system, new multi-electrode QwikStar® catheters 
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(Biosense Webster) enable the sampling of several points simultaneously. This 
feature may allow the construction of maps with more points while decreasing 
manipulation of the LV cavity, resulting in shorter mapping times and greater 
mapping accuracy 16 to guide injections into viable zones. The TAC-HFT trial is 
built on the previous experience obtained in this Phase I, and the Phase I 
Transendocardial Autologous Bone Marrow in Myocardial Infarction (TABMMI) 
trial that treated ten patients and supported the safety of the procedure with 
patients showing sustained benefits 17.   
As of April 27, 2011, only a few clinical trials currently recruiting patients with 
ischemic HF dedicated to treatment by autologous MSCs are ongoing and have 
been registered in clinicaltrials.org website. While the TAC-HFT trial is designed 
to compare BMCs and MSCs, the POSEIDON trial (NCT01087996) is comparing 
autologous and allogenic MSCs. However, there is still a need to compare MSCs 
versus placebo in order to show an effect of MSC therapy in ischemic HF. In this 
process, we are currently leading the phase I of the MESAMI (MESenchymal cell 
therapy And Myocardial Ischemia with decreased left ventricular function) 
program evaluating the safety of injecting MSCs directly into the heart to repair 
and restore heart function in patients who have chronic myocardial ischemia with 
HF (clinicaltrials.org NCT01076920). The multicenter randomized MESAMI 
phase 2 will be dedicated to evaluate versus placebo the effects of MSCs and 
preconditioned MSCs with melatonin following our recent findings 18. 
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Executive summary 
Backgroung: Transcatheter, intramyocardial injections of bone marrow-derived 
cell therapy produces reverse remodeling in large animal models of ischemic 
cardiomyopathy. 
Methods: Eight patients received transendocardial, intramyocardial injection of 
autologous bone marrow progenitor cells (mononuclear or mesenchymal stem 
cells) in left ventricular (LV) scar and border zone. 
Results: All patients tolerated the procedure with no serious adverse events. 
CMR at 1 year demonstrated a decrease in end diastolic volume (208.7±20.4 
versus 167.4±7.32 mL; p=0.03), a trend toward decreased end systolic volume 
(142.4±16.5 versus 107.6±7.4 mL; p=0.06), decreased infarct size (p<0.05), and 
improved regional LV function.  
Discussion: These data suggest that transcatheter, intramyocardial injections of 
autologous bone marrow progenitor cells may improve regional contractility of a 
chronic myocardial scar, and these changes predict subsequent reverse 
remodeling.  
Future perspectives: The findings support the potential clinical benefits of this 
new treatment strategy and ongoing randomized clinical trials. 
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Table 1: Published clinical trials of cardiac cell therapy using bone marrow-derived cells in patients with chronic 
ischemic heart disease associated or not with decreased left ventricular function. 
Study Design Patient 
number 
Disease Cell 
type 
Follow-Up 
(months) 
Primary End Point Imaging 
Modalities 
IACT19 NonRCT 18 Chronic MI BMC 3 LVEF LV angio, 
SPECT, PET 
Tse et al.11 NonRCT 8 Severe ischaemic heart 
disease 
BMC 3 safety LV angiography 
Perin et al.20 RCT 21 Severe, chronic ischemic heart 
failure 
BMC 2-12 myocardial perfusion LV angiography 
TOPCARE-
CHD21 
RCT 75 Stable ischemic heart disease BMC 3 LVEF LV angiography, 
MRI 
TOPCARE-
CHD 
registry22 
Registry 121 Stable ischemic heart disease BMC 18 NTpro-BNP, NTpro-
ANP 
LV angio, SPECT 
Fuchs et al.12 nonRCT 27 Refractory angina BMC 3-12 safety  
van Ramshorst 
et al.23 
RCT 50 Chronic myocardial ischemia BMC 6 myocardial perfusion MRI 
Diederichsen et 
al.24 
NonRCT 32 Congestive heart failure BMC 4 LVEF MRI 
Friis et al.15 NonRCT 31 Refractory angina MSC 6 changes in perfusion 
defects 
Echocardiography 
Ang et al.25 NonRCT 63 Chronic MI BMC 6 LV segmental wall 
motion 
MRI 
TABMMI17 NonRCT 10 Chronic MI BMC 12 LVEF Echocardiography 
Losordo et RCT 24 Refractory angina CD34+ 6 safety  
 16 
al.26 
PROTECT-
CAD27 
RCT 28 Severe coronary artery 
disease 
BMC 6 LVEF SPECT, MRI 
STAR28 NonRCT 191 Ischemic cardiomyopathy BMC 60 LVEF LV angiography 
 
 
RCT: randomized clinical trial, BMC: bone marrow cells, MSC: mesenchymal stem cells, MI, myocardial infarction, 
LVEF: left ventricular ejection fraction. 
 
 
 
 
 
 
